Demonstrates improved prediction of recurrence-free survival in early-stage lung adenocarcinoma, suggesting better patient management.
We established and validated a novel model that integrates radiological, molecular and pathological features to predict RFS in patients with p-stage I LUAD. This new model exhibited excellent discriminatory power for classifying early-stage LUAD patients at different risks of recurrence.
No takes yet. Share an insight, caveat, or question.
Zeng et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: